Meeting
2011 ASCO Annual Meeting
A phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer (BC) (NCIC Clinical Trials Group MA.32).
Authors
W. Parulekar
NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada
W. Parulekar , B. E. Chen , C. Elliott , L. E. Shepherd , K. A. Gelmon , K. I. Pritchard , T. J. Whelan , D. L. Hershman , I. A. Mayer , T. J. Hobday , P. Rastogi , J. Lemieux , P. A. Ganz , V. Stambolic , P. J. Goodwin , J. A. Ligibel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Prevention
Clinical Trial Registration Number
NCT01101438
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS103)
Abstract #
TPS103
Poster Bd #
36E
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).
First Author: Pamela Jean Goodwin
Poster
2022 ASCO Annual Meeting
Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).
First Author: Dawn L. Hershman
Poster
2017 ASCO Annual Meeting
Asymptomatic distant recurrence detection and survival in early stage breast cancer: A nationally representative study.
First Author: Jessica R. Schumacher
Poster
2014 ASCO Annual Meeting
Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).
First Author: Mira F. Liebman